Poster Presentation:  AO-176, a normal cell sparing humanized anti-CD47 antibody

Poster Presentation: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics

[et_pb_section fb_built=”1″ _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_margin=”0px||||false|false” custom_padding=”0px||1%||false|false” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_height=”80px” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.4.8″ max_width=”1080px” custom_margin=”0px||||false|false” custom_padding=”0px||10px||false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” _builder_version=”4.4.8″ title_font=”|600|||||||” title_font_size=”56px” text_orientation=”center” custom_padding=”0px||||false|false”][/et_pb_post_title][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”3.25″ max_width=”960″ use_custom_width=”on” custom_width_px=”960″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″ header_5_font_size=”20px” hover_enabled=”0″ z_index_tablet=”500″]

BRISBANE, CA and ST. LOUIS, MO, March 29, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.

“We are excited to present these new sets of preclinical data at AACR, highlighting the progress our team is making with advancing our novel antibody programs,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.  “The most recent data on AO-176 build on the growing body of research showing that our highly differentiated anti-CD47 antibody selectively binds to and directly kills tumor cells while sparing normal cells. We will continue to work hard to advance AO-176in our ongoing Phase 1 clinical trial in patients with select solid tumors. In addition, we are presenting for the first time preclinical data from our novel, discovery-stage anti-SIRP antibody program.”

Poster Presentations:

Title: AO-176, a normal cell sparing humanized anti-CD47 antibody
Session Date and Time: Sunday, March 31, 2019 1:00 PM – 5:00 PM ET
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23
Poster Board Number: 4
Abstract Number: 540

Title: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics
Session Date and Time:  Sunday, March 31, 2019 1:00 PM – 5:00 PM ET
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23
Poster Board Number: 12
Abstract Number: 548

Copies of these posters will be available as poster sessions on our newsroom page.

About Arch Oncology’s Anti-CD47 Antibody AO-176
AO-176 is a humanized anti-CD47 IgG2 antibody with a best-in-class profile. Arch Oncology’s next-generation anti-CD47 antibody AO-176 is highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class of innate checkpoint inhibitors. AO-176 works by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, AO-176 also works by directly killing tumor cells. Importantly, AO-176 binds preferentially to tumor cells, instead of to normal cells, and binds even more potently to tumors in their acidic microenvironment (low pH). AO-176 is being evaluated in a Phase 1 clinical trial for the treatment of patients with select solid tumors. Additional information about this trial may be found at www.clinicaltrials.gov using the trial identification number NCT03834948.

About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more information please visit www.archoncology.com.

Media Contact:
Amy Figueroa
For Arch Oncology
afigueroa@archoncology.com

View all news

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.4.8″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” da_disable_devices=”off|off|off” disabled=”on” global_module=”6648″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ background_color=”#0191ac” max_width=”1080px” custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ background_color=”#0191ac” custom_padding=”|||” custom_padding__hover=”|||”][/et_pb_column][/et_pb_row][/et_pb_section]

[et_pb_section fb_built=”1″ _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_margin=”0px||||false|false” custom_padding=”0px||1%||false|false” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_height=”80px” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.4.8″ max_width=”1080px” custom_margin=”0px||||false|false” custom_padding=”0px||10px||false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” _builder_version=”4.4.8″ title_font=”|600|||||||” title_font_size=”56px” text_orientation=”center” custom_padding=”0px||||false|false”][/et_pb_post_title][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”3.25″ max_width=”960″ use_custom_width=”on” custom_width_px=”960″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″ header_5_font_size=”20px” hover_enabled=”0″ z_index_tablet=”500″]

— Financing to Advance Lead Anti-CD47 Antibody AO-176 in Ongoing Phase 1 Clinical Trial and Pipeline —

BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.

This financing included Arch Oncology’s existing investors, RiverVest Venture Partners, Roche Venture Fund, and 3×5 Partners, and was led by new investor Lightchain (Scottrade Founder and former CEO Rodger Riney’s family office).

“Our investors share our commitment to the exciting work we are doing to develop best-in-class antibodies aimed at improving treatment options for patients with cancer,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “This financing supports our ongoing Phase 1 clinical trial for AO-176, our highly-differentiated anti-CD47 antibody, as we continue to dose patients. Additionally, these proceeds enable us to advance our discovery-stage pipeline. With the backing of our investors and the hard work of our experienced team, we look forward to developing new cancer treatment options for patients.”

“Over the past year, the Arch Oncology team under Julie’s leadership has successfully executed on plans to advance AO-176 from the laboratory, through IND submission, and into the clinic,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “We believe AO-176 has a best-in-class profile among agents in the anti-CD47 space and we are excited to see the progress advancing the pipeline.”

About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more information please visit www.archoncology.com.

Media Contact:
Amy Figueroa
For Arch Oncology
afigueroa@archoncology.com

View all news

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.4.8″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” da_disable_devices=”off|off|off” disabled=”on” global_module=”6648″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ background_color=”#0191ac” max_width=”1080px” custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ background_color=”#0191ac” custom_padding=”|||” custom_padding__hover=”|||”][/et_pb_column][/et_pb_row][/et_pb_section]